Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy

• Status: Terminated
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effectiveness and safety of the drug GSK189254 in treating patients with narcolepsy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Histamine; Histamine H3 Antagonists

Criteria

Inclusion criteria:

• Narcolepsy patients

• Body mass index between 18 - 32 kg/m2

• Females may be of child bearing or non-child bearing potential.

• Agreement to refrain from driving or operating heavy machinery for the duration of the study.

• Must be able to withdraw from medication for the treatment of daytime sleepiness and must not be living on their own.

Exclusion criteria:

• History or presence of major psychiatric disorder or depression.

• History of significant head trauma in the previous 12 months.

• Participation in a clinical trial in the previous 3 months.

• Patient has significant and recent (within 1 year) history of drug or alcohol abuse.

• Patient is pregnant or breast-feeding.